tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Amedisys (AMED) and ACADIA Pharmaceuticals (ACAD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on HCA Healthcare (HCAResearch Report), Amedisys (AMEDResearch Report) and ACADIA Pharmaceuticals (ACADResearch Report).

HCA Healthcare (HCA)

RBC Capital analyst Ben Hendrix maintained a Buy rating on HCA Healthcare today and set a price target of $256.00. The company’s shares closed last Friday at $173.10, close to its 52-week low of $169.13.

According to TipRanks.com, Hendrix is ranked 0 out of 5 stars with an average return of -13.0% and a 20.9% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Bright Health Group.

Currently, the analyst consensus on HCA Healthcare is a Strong Buy with an average price target of $252.72, representing a 47.5% upside. In a report issued on June 16, Loop Capital Markets also initiated coverage with a Buy rating on the stock with a $240.00 price target.

See today’s best-performing stocks on TipRanks >>

Amedisys (AMED)

In a report released today, Whit Mayo from SVB Securities maintained a Hold rating on Amedisys, with a price target of $107.00. The company’s shares closed last Friday at $121.37, close to its 52-week low of $109.30.

According to TipRanks.com, Mayo is a 4-star analyst with an average return of 5.0% and a 51.4% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Alignment Healthcare, and Privia Health Group.

Currently, the analyst consensus on Amedisys is a Moderate Buy with an average price target of $166.80, implying a 42.5% upside from current levels. In a report released today, Stephens also maintained a Hold rating on the stock with a $125.00 price target.

ACADIA Pharmaceuticals (ACAD)

RBC Capital analyst Gregory Renza maintained a Buy rating on ACADIA Pharmaceuticals today and set a price target of $26.00. The company’s shares closed last Thursday at $19.51.

According to TipRanks.com, Renza ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.7% and a 30.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $26.00 average price target, a 33.4% upside from current levels. In a report issued on June 15, Jefferies also upgraded the stock to Buy with a $25.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HCA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed